Editor's note: Seeking Alpha is proud to welcome Cory Jubinville as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more »
Results for InflaRx’s (NASDAQ: IFRX) Phase II clinical trial of IFX-1, a monoclonal antibody (mAb) targeting C5a to treat Hidradentis Suppurativa ((HS)), indicate IFX-1 exhibits no, to significantly worse patient outcomes when compared to a placebo. Established February 2018, InflaRx’s clinical trial followed patient groups over 16